Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bob Zhong

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
The Journal of Supportive Oncology|February 9, 2008
A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexiaBertram Wiedenmann, Peter Malfertheiner, Helmut Friess, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2015
Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid TumorsJosep Tabernero, Rastislav Bahleda, Rodrigo Dienstmann, et al.
The New England Journal of Medicine|July 25, 2019
Erdafitinib in Locally Advanced or Metastatic Urothelial CarcinomaYohann Loriot, Andrea Necchi, Se Hoon Park, et al.
Future Oncology (London, England)|September 17, 2020
PIVOT-10: Phase II study of bempegaldesleukin plus nivolumab in cisplatin-ineligible advanced urothelial cancerRobert A Huddart, Arlene O Siefker-Radtke, Arjun V Balar, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
The Journal of Supportive Oncology|February 9, 2008
A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexiaBertram Wiedenmann, Peter Malfertheiner, Helmut Friess, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2015
Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid TumorsJosep Tabernero, Rastislav Bahleda, Rodrigo Dienstmann, et al.
The New England Journal of Medicine|July 25, 2019
Erdafitinib in Locally Advanced or Metastatic Urothelial CarcinomaYohann Loriot, Andrea Necchi, Se Hoon Park, et al.
Future Oncology (London, England)|September 17, 2020
PIVOT-10: Phase II study of bempegaldesleukin plus nivolumab in cisplatin-ineligible advanced urothelial cancerRobert A Huddart, Arlene O Siefker-Radtke, Arjun V Balar, et al.
Pageof 2